| Popis: |
Saeed S Akhand,1 Rebecca S Pettit,2 Tonia E Gardner,3 Gregory G Anderson1 1Department of Biology, Indiana University–Purdue University Indianapolis, 2Riley Hospital for Children, Indiana University Health, 3Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA Abstract: In 1989, with the discovery of the genetic mutation causing cystic fibrosis (CF), a cure for this terrible disease seemed just around the corner. Though significant progress has been made to improve the quality of life of CF patients, a remedy for CF is yet to be found. Of great concern, such bacteria as Pseudomonas aeruginosa establish chronic infections that are extremely difficult to eradicate. P. aeruginosa thrives in the CF lung environment, where it protects itself from the host inflammatory defense and contributes immensely to the lung inflammation and tissue destruction seen with the disease. Tackling and eradicating P. aeruginosa infection in the CF lung holds the key to lessen the suffering of these individuals. Unfortunately, current antibiotic regimens are insufficient to eliminate P. aeruginosa from the CF lung. In this review, we address recent drugs that are currently under development to eradicate P. aeruginosa infection in the airways of patients with CF. We discuss the P. aeruginosa infection from the perspective of CF, the shortcomings of current drugs, and the upcoming drugs that are under clinical trials and development. These new drugs and therapies hold much promise for treating recalcitrant P. aeruginosa infections and improving the lives of individuals with CF. Keywords: cystic fibrosis, orphan drugs, Pseudomonas aeruginosa infection |
